Ashraf Azzabi

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

Elizabeth Page, Elizabeth Bancroft, Mark N. Brook et al. · European Urology · 2019 · 240 citations · Full text

Medicine, Oncology, Urology +17

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Timothy Iveson, Rachel Kerr, Mark Saunders et al. · The Lancet Oncology · 2018 · 188 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma

Andy Hughes, Paula Calvert, Ashraf Azzabi et al. · Journal of Clinical Oncology · 2002 · 148 citations

Medicine, Oncology, Pharmacology +16

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard, Laura Murphy, Noel W. Clarke et al. · The Lancet Oncology · 2023 · 102 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study

Elizabeth Bancroft, Elizabeth Page, Mark N. Brook et al. · The Lancet Oncology · 2021 · 93 citations · Full text

Life Sciences, Genetics, Oncology +17